Ohr Pharmaceutical (Nasdaq:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, and leading globalcancer research center Cold Spring Harbor Laboratory (CSHL) announced the establishment of DepYmed Inc., a new joint venture to develop trodusquemine and related analogs. OHR Pharmaceutical Inc (NASDAQ:OHRP) stock opened at $14.73 in last session, and closed at $17.73, while the day range of stock is $14.73 – $17.85. The stock showed a positive weekly performance of 25.30%.
Emergent Biosolutions (NYSE:EBS) posted its quarterly earnings results on Thursday. The company reported $0.42 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.36 by $0.06,AnalystRatingsNetwork reports. Emergent Biosolutions Inc (NYSE:EBS) stock opened at $27.00, in last session and closed at $27.77, by gaining 8.60%. The 52 week range of the stock is $13.02 – $27.96. Company’s market capitalization is $1.01 billion.
Corcept Therapeutics (NASDAQ:CORT) Director Longitude Venture Partners L.P sold 250,000 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $4.00, for a total value of $1,000,000.00. Corcept Therapeutics Incorporated (NASDAQ:CORT) stock advanced 3.16% and finished the last session at $4.08. The EPS of the stock remained -0.46. Company’s market capitalization is $407.24 million.
Analysts at Needham & Company assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA) in a research report issued to clients and investors on Wednesday,TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $22.00 price target on the stock. Genocea Biosciences Inc (NASDAQ:GNCA) stock opened the session at $18.45, and closed the session at $22.45. The 52 week range of the stock remained $10.90 – $19.00 and the day range was $18.45-$22.72.